Recombinant Human Proepiregulin (EREG)
Recombinant Human Proepiregulin (EREG), processed, refers to a genetically engineered form of proepiregulin, a precursor protein involved in cellular signaling pathways. This partially processed variant is produced by recombinant technology and may retain specific functional domains or structural features relevant to its biological activity, serving as a tool for studying molecular mechanisms or as a potential therapeutic agent.
Applications
Cell Signaling Research
EREG can be used as a tool to investigate the signaling pathways involved in cellular proliferation, differentiation, and migration. Its partial processing may allow for the study of specific regulatory mechanisms or interactions with other molecules.
Tissue Regeneration
EREG has been implicated in wound healing and tissue regeneration processes. Recombinant EREG may be explored for its potential to promote tissue repair and regeneration in various medical applications.
Drug Development
EREG and its signaling pathways are potential targets for drug development in various diseases, including cancer, inflammatory disorders, and cardiovascular diseases. Recombinant EREG can be utilized in preclinical studies to assess the efficacy and safety of novel therapeutic agents.
Featurures
Biological Activity
Despite being partially processed, recombinant EREG retains its biological activity, allowing it to interact with its receptors and initiate cellular signaling pathways accurately.
Reproducibility
Production of recombinant EREG through genetic engineering techniques ensures consistency and reproducibility, facilitating its use in research, biopharmaceutical development, and clinical applications.
Scalability
Recombinant EREG can be produced under stringent quality control measures to ensure purity and safety, minimizing the risk of contamination or adverse effects in experimental or therapeutic settings.